Document is current
Any future updates will be listed below
-
Authors
Van Meerbeeck, Pierre
Maatougui, Douae
de Streel, Grégoire
Vaherto, Noora
Marbaix, Etienne
Aboubakar Nana, Frank
Van den Eynde, Marc
Devaux, Alix
Carrasco, Javier
Noel, Agnès
van Baren, Nicolas
Lucas, Sophie
-
Funding
Funding for this research was provided by:
Fonds De La Recherche Scientifique - FNRS (PDR-TLV#40007289, PDR-TLV#40007447)
FNRS (Postdoctoral Researcher)
WEL Research Institute, WELBIO Department (CR-2019A-02 and CR-2019A-02 R)
- License Information
-
More Information
Article History
Received: 15 April 2025
Accepted: 22 August 2025
First Online: 13 September 2025
Declarations
:
: Patents pertaining to blocking antibodies against human GARP:TGF-β1 have been filed under the Patent Cooperation Treaty (International application Number PCT/IB2019/053753), with Sophie Lucas as inventor and UCLouvain as applicant. Anti-human GARP:TGF-β1 antibodies have been licensed to AbbVie.
: Any information required to reanalyze the data reported in this paper is available from the lead contact upon request. This includes the in-house computer scripts written in the R programming language (v.4.3.1) that were developed to carry out the quantitative image analyses.
